EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab

Konstantinos C Koskinas iD, Jonas Häner iD, Yasushi Ueki iD, Tatsuhiko Otsuka iD, Jacob Lonborg, Hiroki Shibutani iD, Ryota Kakizaki iD, Christoph Kaiser, Robert-Jan van Geuns iD, Anna S Ondracek iD, Fabien Praz iD, Maria Ambühl und 12 weitere

Circulation: Cardiovascular Imaging · 2024

DOI: 10.1161/circimaging.124.016683 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Circulation: Cardiovascular Imaging, 2024. Verfasst von Konstantinos C Koskinas und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Bern University Hospital, Inselspital (K.C.K., J.H., Y.U., T.O., H.S., R.K., F.P., M.A., J. Lanz, S.W., L.R.), University o…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Biomarkers, Coronary Artery Disease, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Elevated Lp(a) (lipoprotein[a]) is a risk marker for atherosclerotic disease, but the underlying mechanisms remain elusive. We examined the association of Lp(a) with changes in coronary atherosclerosis following intensive lipid-lowering therapy. METHODS: In the PACMAN-AMI trial (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction), 300 patients with acute myocardial infarction were randomized to receive biweekly alirocumab 150 mg or placebo in addition to high-intensity statins. Patients underwent serial 2-vessel intravascular ultrasound, optical coherence tomography, and near-infrared spectroscopy in the non–infarct-related arteries at baseline and after 52 weeks. The main end points were percent atheroma volume by intravascular ultrasound, minimum fibrous cap thickness by optical coherence tomography, and maximum lipid core burden index within 4 mm (maxLCBI 4mm ) by near-infrared spectroscopy. RESULTS: A total of 265 patients had serial intravascular ultrasound data (mean age, 58±9 years; 16% women). Alirocumab resulted in greater reductions in percent atheroma volume and maxLCBI 4mm , as well as a greater increase in minimum fibrous cap thickness, compared with placebo. In the alirocumab group, the reduction in maxLCBI 4mm was smaller in patients with higher baseline Lp(a), defined by the highest quartile (Q4, ≥98 nmol/L; n=30), than in those with lower baseline Lp(a) (Q1–Q3,

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedBiomarkersCoronary Artery DiseaseHydroxymethylglutaryl-CoA Reductase InhibitorsLipoprotein(a)Plaque, AtheroscleroticTomography, Optical CoherenceUltrasonography, InterventionalAgedFemaleHumansMaleMiddle AgedAnticholesteremic AgentsCoronary VesselsDouble-Blind MethodDrug Therapy, CombinationMyocardial InfarctionPCSK9 InhibitorsSpectroscopy, Near-InfraredTime FactorsTreatment OutcomeProprotein Convertase 9

Stichwörter der Autor:innen

atherosclerosiscoronary artery diseaseslipoprotein(a)

Substanzen

Antibodies, Monoclonal, HumanizedAnticholesteremic AgentsBiomarkersHydroxymethylglutaryl-CoA Reductase InhibitorsLipoprotein(a)PCSK9 InhibitorsalirocumabLPA protein, humanPCSK9 protein, humanProprotein Convertase 9

Autor:innen und Institutionen

  • Department of Cardiology, Bern University Hospital, Inselspital (K.C.K., J.H., Y.U., T.O., H.S., R.K., F.P., M.A., J. Lanz, S.W., L.R.), University of Bern, Switzerland.
  • Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Denmark (J. Lonborg, T.E.).
  • Department of Cardiology, University Hospital Basel, Switzerland (C.K.).
  • Department of Cardiology, Radboud UMC, Nijmegen, the Netherlands (R.-J.v.G.).
  • Department of Cardiology, Medical University of Vienna, Austria (A.S.O., M.M.; I.M.L.).
  • Institute of Pharmacology, Bern University Hospital (D.S.), University of Bern, Switzerland.

ORCID-Profile: Konstantinos C Koskinas, Jonas Häner, Yasushi Ueki, Tatsuhiko Otsuka, Hiroki Shibutani, Ryota Kakizaki, Robert-Jan van Geuns, Anna S Ondracek, Fabien Praz, Jonas Lanz, Joost Daemen, Dik Heg, Manuel Mayr, François Mach, Stephan Windecker, Thomas Engstrøm, Irene M Lang, Arnold von Eckardstein, Lorenz Räber

Zitieren

APA

Koskinas, K. C., Häner, J., Ueki, Y., Otsuka, T., Lonborg, J., Shibutani, H., Kakizaki, R., Kaiser, C., van Geuns, R. J., Ondracek, A. S., Praz, F., Ambühl, M., Spirk, D., Lanz, J., Daemen, J., Heg, D., Mayr, M., Mach, F., Windecker, S., …, & Räber, L. (2024). Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab. Circulation: Cardiovascular Imaging. https://doi.org/10.1161/circimaging.124.016683

Vancouver

Koskinas KC, Häner J, Ueki Y, Otsuka T, Lonborg J, Shibutani H, et al. Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab. Circulation: Cardiovascular Imaging. 2024. doi:10.1161/circimaging.124.016683

BibTeX
@article{Koskinas2024,
  author = {Koskinas, Konstantinos C and Häner, Jonas and Ueki, Yasushi and Otsuka, Tatsuhiko and Lonborg, Jacob and Shibutani, Hiroki and Kakizaki, Ryota and Kaiser, Christoph and van Geuns, Robert-Jan and Ondracek, Anna S and Praz, Fabien and Ambühl, Maria and Spirk, David and Lanz, Jonas and Daemen, Joost and Heg, Dik and Mayr, Manuel and Mach, François and Windecker, Stephan and Engstrøm, Thomas and Lang, Irene M and von Eckardstein, Arnold and Losdat, Sylvain and Räber, Lorenz},
  title = {Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab},
  journal = {Circulation: Cardiovascular Imaging},
  year = {2024},
  doi = {10.1161/circimaging.124.016683}
}
Kostenlos starten →